News
Intellia will present additional interim clinical data from the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with…
Intellia will present its fourth quarter and full-year 2021 financial results.
* To join the call, U.S. callers should dial 1-833-316-0545 and international…
The Rare Disease Day Symposium at the Quinnipiac Frank H. Netter MD School of Medicine is unique to the state of Connecticut in addition to a global event that…
Rare Disease Day(R) takes place worldwide, typically on or near the last day of February each year, to raise awareness among policymakers and the public about rare…
The National Organization for Rare Disorders (NORD(R)), in collaboration with the Rare Disease Diversity Coalition (RDDC), is pleased to announce the second webinar…
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based…
Cardiac amyloidosis is not nearly as rare as one might think, and with effective treatments finally emerging in recent years, there's a need to increase awareness…
Join NHLBI, The Heart Truth(R), and organizations around the country throughout February and National Wear Red Day(R) on February 3rd, 2023 to bring greater…
The treatment uses CRISPR/Cas9 editing technology, a technique derived from bacteria that allows researchers to edit the genome of a cell by specifying regions of…
Investigators have found that intravenous infusion of a CRISPR-Cas9 based gene therapy decreases serum transthyretin (TTR) protein in patients with hereditary TTR…